124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Disease details / Clinical trials / Drug dev / DR info

Clinical trials : 17 /  Drugs : 19 - (DrugBank : 9) / Drug target genes : 6 - Drug target pathways : 24

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
0.9 % nacl
   Ever Neuro Pharma GmbH
      2023   Phase 2   NCT05755997   Czechia
6R-BH4
   AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
      2007   -   EUCTR2007-004370-55-IT   Italy
Adrenomedullin
   Ihara Masafumi
      2022   Phase 2   JPRN-jRCT2051210117   -
   National Cerebral and Cardiovascular Center, Japan
      2022   Phase 2   NCT06072118   Japan
Antiplatelets
   S. Andrea Hospital
      2011   Phase 2   NCT01361763   Italy
Aricept
   EISAI LTD UK
      2005   -   EUCTR2004-001162-40-IT   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Eisai Limited
      2005   Phase 2   NCT00103948   Australia;Canada;Finland;France;Germany;Italy;Spain;Sweden;Switzerland;United Kingdom;United States
   Eisai Ltd
      2005   -   EUCTR2004-001162-40-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-GB   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-FI   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-ES   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      -   -   EUCTR2004-001162-40-DE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
Cerebrolysin
   Ever Neuro Pharma GmbH
      2023   Phase 2   NCT05755997   Czechia
Cilostazol
   Mayo Clinic
      2021   Phase 1/Phase 2   NCT04753970   United States
Dabigatran
   S. Andrea Hospital
      2011   Phase 2   NCT01361763   Italy
Donepezil
   EISAI LTD UK
      2005   -   EUCTR2004-001162-40-IT   Finland;Germany;Italy;Spain;Sweden;United Kingdom
Donepezil hydrochloride
   Eisai Ltd
      2005   -   EUCTR2004-001162-40-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-GB   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-FI   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-ES   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      -   -   EUCTR2004-001162-40-DE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
E2020
   Eisai Ltd
      2005   -   EUCTR2004-001162-40-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-GB   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-FI   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2005   Phase 2   EUCTR2004-001162-40-ES   Finland;Germany;Italy;Spain;Sweden;United Kingdom
      -   -   EUCTR2004-001162-40-DE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
Fremanezumab
   Mayo Clinic
      2021   Phase 2   NCT04334408   United States
HOV-12020
   Hovid Berhad
      2020   Phase 2   NCT04658823   France
Lomerizine
   Ohara Tomoyuki
      2022   -   JPRN-jRCTs051220072   -
LOW-FAT control diet
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2024   -   NCT06933212   Italy
Mediterranean diet with extra virgin olive OIL
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2024   -   NCT06933212   Italy
Mediterranean diet with walnuts
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2024   -   NCT06933212   Italy
Phenoptin
   AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
      2007   -   EUCTR2007-004370-55-IT   Italy
Sapropterin
   AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
      2007   -   EUCTR2007-004370-55-IT   Italy